Acrivon Therapeutics
Acrivon Therapeutics is seeking an accomplished R&D leader to provide scientific and strategic leadership for the company's drug discovery and research activities. The role involves driving data-driven analysis of proprietary phosphoproteomic data, integrating discovery and clinical data, and guiding translational strategies to advance programs from target evaluation through clinical Phase 2 proof of concept. The position requires a data-driven scientific leader with extensive experience in small-molecule oncology drug development and strong executive-level communication skills.
Headquarters
Cambridge, Massachusetts, United States
Company Size
11-50 employees
Founded
2018
Acrivon Therapeutics is a clinical-stage biopharmaceutical company focused on precision oncology, developing targeted therapies designed to improve outcomes for cancer patients. The company leverages its proprietary AP3 platform, a proteomics-based patient selection method, to match drug mechanisms to the biological drivers of cancer and identify patients whose tumors are predicted to be sensitive to its drug candidates. Its pipeline includes ACR-368 (Prexasertib), a CHK1/2 kinase inhibitor in Phase 2 development, as well as internally developed candidates ACR-2316 and ACR-6840, targeting DNA Damage Response, cell cycle, and transcriptional regulators.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Acrivon Therapeutics.
26% above the average for this role
Translational Lead
Tonix Pharmaceuticals
Vice President of Translational Medicine
Flagship Pioneering, Inc.
Sr. Leader Discovery Toxicology
Inotiv
Translational Research Senior Director
Sumitomo Pharma America, Inc
Chief Scientist, Modern Drug Discovery
lifelancer
Chief Scientist, Modern Drug Discovery
lifelancer